StockMarketWire.com - Goldman Sachs today reaffirms its buy investment rating on GlaxoSmithKline PLC [LON:GSK] and cut its price target to 2020p (from 2060p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk